King Pharmaceuticals vs. Alpharma - Biggest Battles in Biopharma

King Pharmaceuticals vs. Alpharma

In August 2008, King Pharmaceuticals tried to woo Alpharma with $1.38 billion cash offer. King wasn't prepared to take no for an answer, and it was ready to get hostile if necessary to push the acquisition through.

But Alpharma wasn't as enthusiastic and rejected the offer. Alpharma claimed it had other companies interested in a buyout, but King pushed forward with the hostile bid. King also threatened a proxy battle if Alpharma continued to reject its offers.

Despite Alpharma's repeated objections, a $1.6 billion offer eventually piqued its interest

King Pharmaceuticals vs. Alpharma - Biggest Battles in Biopharma

Suggested Articles

Imbruvica has enjoyed a nice run in previously untreated CLL over the last few years. But major competition is here in the form of AZ's Calquence.

Pennsylvania's Supreme Court revived thousands of lawsuits alleging the antipsychotic med Risperdal caused males to develop breasts.

In the asthma biologics race, there doesn't appear to be a clear favorite among Xolair, Dupixent, Fasenra and Nucala for a group of pulmonologists.